A major challenge in the field of hepatology is the fight against hepatitis C that affects more than 150 million people world-wide. Despite the enormous improvement that has been achieved in the therapy of chronic hepatitis C over the last decade, there is an urgent medical need for new therapeutic approaches. This review focuses on the optimization of the current standard therapy of hepatitis C and future treatment directions beyond pegylated interferon alpha and ribavirin.